The specter of generic competition has repeatedly loomed around copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the prospects of connected pharmaceutical ventures. While first periods saw significant gains, the exclusivity expiration has allowed the path for cheaper alternatives, possibly diminishing revenue and presenting a